Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Positive recommendation based on resmetirom’s favorable profile including positive results from the pivotal Phase 3 MAESTRO-NASH trialEuropean Commission decision expected in August 2025; if approved,...
-
XOANACYL is an oral therapy designed to address critical challenges in CKD, including Iron deficiency and hyperphosphatemia Averoa submitted XOANACYL for UK approval via MHRA’s International...
-
TORONTO, June 12, 2025 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0), an artificial intelligence (AI) solutions company...
-
Now approved in the EU, Duvyzat offers an important treatment option for delaying Duchenne muscular dystrophy (DMD) disease progressionDuvyzat is an orally administered treatment for DMD in patients 6...
-
Austin, TX, USA, May 20, 2025 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Pharmaceutical Contract Packaging Market Size, Trends and Insights By Type...
-
Enrollment and dosing underway in Phase 3 clinical trial (the “MIRACLE” trial) evaluating Annamycin (naxtarubicin) for the treatment of R/R AML Regulatory and site selection progress to date...
-
NurExone Expands European Engagement with Investor Events in Germany and Switzerland
-
Austin, TX, USA, April 28, 2025 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Regenerative Medicine Market Size, Trends and Insights By Product (Serum-free...
-
Recommendation is based on Phase 3 EPIDYS trial data that demonstrated Duvyzat (givinostat) provides statistically and clinically meaningful treatment benefits in individuals with Duchenne muscular...
-
Lugano, Switzerland – April 2, 2025 – Helsinn Group (“Helsinn”), a global pharmaceutical company with a track record of nearly fifty years of commercial execution and a strong focus in supportive...